

Course Syllabus



American Academy of Addiction Psychiatry

Addictions and Their Treatment

September 22 and 23, 2023 | Virtual

Accreditation Statement:



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Target Audience Statement

The field of Addiction changes frequently as new information becomes available. This course presents a broad-based overview of addictions and up-to-date information in the field of addiction. It is recommended for physicians, PA-Cs, nurse practitioners, and other professionals who wish to stay updated on the most recent trends in the addiction field. It is equally relevant to junior faculty and clinicians as well as experienced practitioners and is intended to help psychiatrists prepare for ABPN certification and recertification examinations in Addiction Psychiatry.

The activity was designated for learners in the following ways:

Physician Designation Statement

American Academy of Addiction Psychiatry designates this Other activity (33 hours of enduring material and 8 hours of live online) for a maximum of 41 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABPN Diplomates

The American Board of Psychiatry and Neurology has reviewed AAAP's 2023 Addictions and Their Treatment and has approved this program as part of a comprehensive self-assessment program, which is mandated by the ABMS as a necessary component of maintenance of certification. This activity awards 10 Self-Assessment Category 1 CME Credits. The approval period is through June 6, 2026.

AAPA Designation Statement

PAs may claim a maximum of 41 Category 1 credits for completing this activity. NCCPA accepts *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioners and Registered Nurses

For the purpose of recertification, the American Nurses Credentialing Center accepts *AMA PRA Category 1 Credit™* issued by organizations accredited by the ACCME.

Health

Professionals

Designation

Statement

Participants will receive a Certificate of Attendance stating this program is designated for 41 *AMA PRA Category 1 Credits™*. This credit is accepted by the AANP.

Educational Objectives:

At the conclusion of this activity, participants should be able to:

1. Describe new advances in pharmacotherapy and psychotherapy of substance use disorders.
2. Discuss the epidemiology of substance use disorders and their co-occurrence with other psychiatric disorders and review current recommended approaches for concurrent treatment of substance use disorders and other mental health disorders.
3. Describe the role of genetics in the risk for developing alcohol and other substance use disorders.
4. Identify the major neurobiological pathways involved in substance disorders.
5. Identify the molecular mechanisms that are altered following substance use.
6. Review the literature on screening and brief intervention effectiveness and teach this technique so it is applied.
7. Review current treatment guidelines and how to utilize them in clinical practice.
8. Describe special considerations for substance use diagnosis and treatment for women, underrepresented racial and ethnic minorities, youth, older adults, hospitalized patients, and patients with comorbid health conditions.

Faculty:

- Steven L. Batki, MD
- Adina Bowe, MD
- Kathleen T. Brady, MD, PhD
- Roger Chou, MD, FACP
- Timothy W. Fong MD
- Petros Levounis, MD, MA
- Michelle Lofwall, MD
- David Marcovitz, MD
- Carla Marienfeld, MD, DFAPA, FASAM
- Sanchit Maruti, MD, MS
- Edward V. Nunes, MD
- John A. Renner, Jr., MD
- Richard K. Ries, MD
- Kevin A. Sevarino, MD, PhD
- Laurence M. Westreich, MD
- Louis Trevisan, MD
- Jill Williams, MD
- Amy Yule, MD

Topics:

- Alcohol
- Behavioral Addictions
- Benzodiazepines: The Hidden Epidemic
- Cannabis
- Co-Morbidity of Substance and other Psychiatric Disorders
- Emerging Drugs
- Forensic Issues in Addiction
- General Concepts and Epidemiology
- Inequities in Addiction Treatment for Racial and Ethnic Minority Populations
- Medical Comorbidities in Patients with Substance Use Disorders
- Motivational Interviewing
- Naloxone Overdose Training
- Neurobiology and Genetics
- Pain and Addiction
- Pregnancy and Substance Use Disorders
- Psychosocial Treatments of the Addictions
- Review of Opioids and Treatment of Opioid Use Disorders
- Sex and Drugs: Gender Differences in Substance Use Disorders
- Stimulant-Related Disorders
- Substance Use Disorders In the Older Population
- Substance Use Disorder Treatment in Hospital Settings
- Suicide and Substance Use Disorders
- Tobacco
- Urine Drug Testing
- Youth with Substance Use Disorders and ADHD

Schedule:

Friday, September 22, 2023	
12:30 PM	Welcome and Introduction to the Live Session
12:35 PM – 2:15 PM	Kevin A. Sevarino MD, PhD <ul style="list-style-type: none">● General Concepts and Epidemiology● Neurobiology and Genetics● Urine Drug Testing David Marcovitz, MD <ul style="list-style-type: none">● Alcohol Roger Chou, MD <ul style="list-style-type: none">● Pain and Addiction
2:15 PM – 2:30 PM	Break
2:30 PM – 3:50 PM	Edward V. Nunes, MD <ul style="list-style-type: none">● Co-Morbidity of Substance and Other Psychiatric Disorders● Psychosocial Treatment of the Addictions Jill Williams, MD <ul style="list-style-type: none">● Tobacco and Nicotine Adina Bowe, MD <ul style="list-style-type: none">● Inequities in Addiction Treatment for Racial and Ethnic Minority Populations
3:50 PM – 4:05 PM	Break
4:05 PM – 5:25 PM	Steven L. Batki, MD <ul style="list-style-type: none">● Stimulant-Related Disorders● Medical Comorbidities in Patients with Substance Use Disorders Kathleen T. Brady, MD, PhD <ul style="list-style-type: none">● Sex and Drugs: Gender Differences in Substance Use Disorders Carla Marienfeld, MD <ul style="list-style-type: none">● Motivational Interviewing
5:25 PM – 5:30 PM	End of Day Wrap Up
Saturday, September 23, 2023	
11:00 AM	Welcome and Introduction to the Live Session
11:05 AM – 12:25 PM	Michelle Lofwall, MD <ul style="list-style-type: none">● Pregnancy and Substance Use Disorders● Naloxone Overdose Training John A. Renner, Jr., MD <ul style="list-style-type: none">● Review of Opioids and Treatment of Opioid Use Disorders Sanchit Maruti, MD <ul style="list-style-type: none">● Substance Use Disorder in Hospital Settings
12:25 PM – 12:40 PM	Break

12:40 PM – 2:00 PM	Sanchit Maruti, MD - Live Q&A Presenter Richard Ries, MD - On-Demand Session Presenter <ul style="list-style-type: none"> ● Suicide and Substance Use Disorders ● Benzodiazepines: The Hidden Epidemic Louis Trevisan, MD <ul style="list-style-type: none"> ● Substance Use Disorders in the Older Adult Amy M. Yule, MD <ul style="list-style-type: none"> ● Youth with Substance Use Disorders and Attention Deficit Hyperactivity Disorder
2:00 PM – 2:15 PM	Break
2:15 PM – 3:35 PM	Petros Levounis, MD, MA <ul style="list-style-type: none"> ● Cannabis ● Emerging Drugs Laurence M. Westreich, MD <ul style="list-style-type: none"> ● Forensic Issues in Addiction Timothy W. Fong, MD <ul style="list-style-type: none"> ● Behavioral Addictions
3:35 PM – 3:40 PM	End of Day Wrap Up

Disclosure to Learners:

In accordance with the disclosure policy of the American Academy of Addiction Psychiatry, as well as standards set forth by Joint Accreditation for Interprofessional Continuing Education policies and accreditation requirements including the Standards for Integrity and Independence in Accredited Continuing Education, AAAP is expected to present learners with unbiased, independent, and objective information in all of our activities. Therefore, planners, faculty, and all others involved in the planning or content development of this activity must disclose all financial and professional relationships with ineligible companies that have occurred within the past 24 months.

The following faculty has relevant financial relationships with an ineligible company to disclose:

Michelle Lofwall, MD

Titan Pharmaceuticals

Consultant

All of the relevant financial relationships listed for these individuals have been mitigated. All other planners, faculty, and others in control of the planning and presentation of this activity have no relevant financial relationships with ineligible companies.

All speakers have been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in the presentation must conform to the generally accepted standards of experimental design, data collection, and analysis.